Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Helicobacter pylori's helical shape helps it colonize the stomach

The bacterium Helicobacter pylori, which lives in the human stomach and is associated with ulcers and gastric cancer, is shaped like a corkscrew, or helix. For years researchers have hypothesized that the bacterium's twisty shape is what enables it to survive - and thrive - within the stomach's acid-drenched environment, but until now they have had no proof.

28 May 2010

Advanced Life Sciences expands partnership with U.S. Government to assess Restanza against STI's

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced the expansion of its collaboration with the U.S. Government to include the evaluation of Restanza's activity against sexually transmitted infections (STI's), such as gonorrhea.

28 May 2010

Researchers see plectasin as promising lead compound for new antibiotics

An active compound from fungi and lower animals may well be suitable as an effective weapon against dangerous bacteria. We're talking about plectasin, a small protein molecule that can even destroy highly resistant bacteria . Researchers at the Universities of Bonn, Utrecht, Aalborg and of the Danish company Novozymes AS have shed light on how the substance does this.

28 May 2010

CrystalGenomics to merge with BexPharm

CrystalGenomics, Inc., a leading biopharmaceutical company developing novel small molecule therapeutics announced today that it will merge with BexPharm, a specialty pharmaceutical company that imports and distributes foreign market approved drugs in Korea.

28 May 2010

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge.

28 May 2010

National Science Foundation supports PolyMedix with $150,000 grant for development of antimicrobial sutures

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat serious acute cardiovascular disorders and infectious diseases, has received a grant in the amount of $150,000 from the National Science Foundation to support the development of antimicrobial sutures. PolyMedix has developed a series of novel antimicrobial polymers for device and material applications, which it collectively calls the PolyCides™.

27 May 2010

Bacteria may play wider role in people predisposed to obesity: Researchers

Bacteria may play more of a role in people predisposed to obesity than previously thought, according to studies presented today by University of Maryland School of Medicine researchers at the 110th general meeting of the American Society for Microbiology in San Diego.

27 May 2010

Restanza shows greater efficacy against species of Plasmodium that cause malaria

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from in vitro and in vivo studies assessing the efficacy of Restanza (cethromycin), its novel oral antibiotic, against the species of Plasmodium that cause malaria.

27 May 2010

Researchers examine association between use of antibiotics and outcomes among patients with COPD

Among patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease, those who received antibiotics in the first 2 hospital days had improved outcomes, such as a lower likelihood of mechanical ventilation and fewer readmissions, compared to patients who received antibiotics later or not at all, according to a study in the May 26 issue of JAMA.

26 May 2010

Dangerous bacterium appears in Australia for the first time

Clostridium difficile is a bacterium that has killed thousands abroad. Now is has been detected in three Australians for the first time. The bacterium was detected in three patients at Melbourne's Epworth Hospital.

25 May 2010

NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today announced the completion of enrollment in a Phase 2a proof-of-concept trial for the treatment of impetigo.

25 May 2010

USPTO issues composition of matter patent for Transave's ARIKACE

Transave Inc. today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 7,718,189) for liposomal aminoglycoside formulations including its lead compound, ARIKACE™ (liposomal amikacin for inhalation). The company expects that the patent will provide exclusivity for ARIKACE until October 1, 2026.

25 May 2010

Wolf Medical Supply, I-Flow settle patent dispute on Redi-Flo Infusion Pump

Wolf Medical Supply, Inc. and I-Flow Corporation, a division of Kimberly-Clark Corporation, have settled out of court ending the patent dispute regarding the Redi-Flo™ Infusion Pump.

25 May 2010

Natural anti-inflammatory protein effective against meningitis-causing bacteria

A study published online on May 24th in the Journal of Experimental Medicine (www.jem.org) suggests that boosting the abundance of one of the body's own proteins might be more effective than antibiotic treatment at fighting off a common meningitis-causing bacterium (E. coli K1).

25 May 2010

Baxa announces release of InFuse T-10 Syringe Infuser

Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations and increase patient safety, today announced the release of the InFuse T-10 Syringe Infuser. Specifically designed for the delivery of intermittent antibiotics and other non-rate critical intravenous doses, the Baxa InFuse T-10 Syringe Infuser frees up expensive, smart infusion pumps for more critical applications and gives nurses more time to focus on patient care.

24 May 2010

BinaxNOW PBP2a test to detect PBP2a in MRSA

AdvanDx today announced that it will offer the BinaxNOW PBP2a test from Inverness Medical Innovations, Inc. (Waltham, MA) to customers in the United States. The test provides rapid detection of the penicillin-binding protein 2a present in Methicillin-Resistant Staphylococcus aureus (MRSA) directly from S. aureus positive blood cultures.

24 May 2010

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Salix Pharmaceuticals, Ltd. today announced the availability of Xifaxan (rifaximin) 550 mg tablets for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. Those HE patients may now fill their Xifaxan 550 mg prescriptions in U.S. pharmacies and should speak with their doctors about this important treatment option.

24 May 2010

Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval by the Swedish Medical Products Agency to commence a Phase I/IIa clinical trial with Lytixar (LTX-109) for nasal decolonisation of MRSA.

24 May 2010

Sorrento Therapeutics receives STTR grant to develop antibody therapeutics to combat MRSA

Sorrento Therapeutics, Inc. today announced that it has received an Advanced Technology Small Business Technology Transfer Research grant from the National Institute of Allergy and Infectious Diseases. The peer-reviewed grant was awarded to support the Company's program to generate and develop novel antibody therapeutics and vaccines to combat Staphylococcus aureus infections, including methicillin-resistant S. aureus, by disrupting quorum sensing, a bacterial communication process essential to virulence.

21 May 2010

Vesicoureteral reflux more common among girls

Children with vesicoureteral reflux (VUR), in which urine flows backwards into the kidneys from the bladder, have been treated in the past with surgery or antibiotic therapy.

21 May 2010

Antibiotic News and Research

Further Reading

Helicobacter pylori's helical shape helps it colonize the stomach

Advanced Life Sciences expands partnership with U.S. Government to assess Restanza against STI's

Researchers see plectasin as promising lead compound for new antibiotics

CrystalGenomics to merge with BexPharm

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

National Science Foundation supports PolyMedix with $150,000 grant for development of antimicrobial sutures

Bacteria may play wider role in people predisposed to obesity: Researchers

Restanza shows greater efficacy against species of Plasmodium that cause malaria

Researchers examine association between use of antibiotics and outcomes among patients with COPD

Dangerous bacterium appears in Australia for the first time

NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo

USPTO issues composition of matter patent for Transave's ARIKACE

Wolf Medical Supply, I-Flow settle patent dispute on Redi-Flo Infusion Pump

Natural anti-inflammatory protein effective against meningitis-causing bacteria

Baxa announces release of InFuse T-10 Syringe Infuser

BinaxNOW PBP2a test to detect PBP2a in MRSA

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA

Sorrento Therapeutics receives STTR grant to develop antibody therapeutics to combat MRSA

Vesicoureteral reflux more common among girls

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News